이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Humacyte 관리

관리 기준 확인 2/4

Humacyte's CEO는 Laura Niklason, Jan2004 에 임명되었습니다 의 임기는 20.42 년입니다. 총 연간 보상은 $ 2.63M, 23% 로 구성됩니다. 23% 급여 및 77% 보너스(회사 주식 및 옵션 포함). 는 $ 1.43M 가치에 해당하는 회사 주식의 0.2% 직접 소유합니다. 1.43M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 2.8 년입니다.

주요 정보

Laura Niklason

최고 경영자

US$2.6m

총 보상

CEO 급여 비율	23.0%
CEO 임기	20.4yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Recent updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

May 14

CEO 보상 분석

Laura Niklason 의 보수는 Humacyte 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$106m
Dec 31 2023	US$3m	US$604k	-US$111m
Sep 30 2023	n/a	n/a	-US$89m
Jun 30 2023	n/a	n/a	-US$89m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$2m	US$500k	-US$12m
Sep 30 2022	n/a	n/a	US$34m
Jun 30 2022	n/a	n/a	US$28m
Mar 31 2022	n/a	n/a	-US$26m
Dec 31 2021	US$11m	US$500k	-US$26m
Sep 30 2021	n/a	n/a	-US$85m
Jun 30 2021	n/a	n/a	-US$71m
Mar 31 2021	n/a	n/a	-US$69m
Dec 31 2020	US$619k	US$75k	-US$67m

보상 대 시장: Laura 의 총 보상 ($USD 2.63M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 3.43M ).

보상과 수익: 회사가 수익성이 없는 동안 Laura 의 보상이 증가했습니다.

CEO

Laura Niklason (61 yo)

20.4yrs

테뉴어

US$2,625,702

보상

Dr. Laura E. Niklason, M.D., Ph D., serves as President and Chief Executive Officer at Humacyte, Inc. since November 2020. She founded Humacyte, Inc. in 2004 and served as its Chief Scientist from 2005 to...

리더십 팀

이름	위치	테뉴어	보상	소유권
Laura Niklason	Founder	20.4yrs	US$2.63m	0.20% $ 1.2m
Dale Sander	CFO, Chief Corporate Development Officer & Treasurer	3.6yrs	US$1.35m	0.019% $ 115.3k
Heather Prichard	Chief Operating Officer	5.1yrs	US$1.27m	0% $ 0
Juliana Blum	Co-Founder & Executive Advisor	no data	데이터 없음	데이터 없음
Sabrina Osborne	Executive Vice President of Business Strategy & People	no data	데이터 없음	데이터 없음
William Scheessele	Chief Commercial Officer	2.8yrs	데이터 없음	0.013% $ 79.2k
Shamik Parikh	Chief Medical Officer	2.2yrs	US$1.53m	0% $ 0
Harold Alterson	Senior Vice President of Quality	1.8yrs	데이터 없음	데이터 없음
Yang Cao	Chief Regulatory Officer	1.8yrs	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: HUMA 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Laura Niklason	Founder	20.4yrs	US$2.63m	0.20% $ 1.2m
Gordon Binder	Independent Director	2.8yrs	US$71.76k	0.18% $ 1.1m
Max Wallace	Independent Director	19yrs	US$76.76k	0.054% $ 329.2k
Brady Dougan	Director	19.4yrs	US$71.76k	0.43% $ 2.6m
Susan Windham-Bannister	Independent Director	2.8yrs	US$71.76k	0% $ 0
Todd Pope	Independent Director	no data	US$76.76k	0% $ 0
Rajiv Shukla	Director	2.8yrs	US$71.76k	1.52% $ 9.3m
Kathleen Sebelius	Independent Chairman of the Board	8.8yrs	US$96.76k	0.033% $ 200.9k
Michael Constantino	Independent Director	no data	US$79.26k	0.0078% $ 47.2k
Diane Seimetz	Independent Director	2yrs	US$71.76k	0% $ 0
Emery Brown	Independent Director	2.8yrs	US$71.76k	0% $ 0
C. Green	Independent Director	1.8yrs	US$71.76k	0% $ 0

2.8yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: HUMA 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Humacyte 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Recent updates

Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp™?) Program

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

Humacyte, Inc. to Report Q1, 2024 Results on May 10, 2024

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 7.1% to US$7.50

New major risk - Revenue and earnings growth

Humacyte, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

New minor risk - Shareholder dilution

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel (Hav) for the Treatment of Vascular Trauma

Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel™? (HAV™?) in the Treatment of Vascular Trauma

Humacyte, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel™? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model

Founder exercised options to buy US$280k worth of stock.

Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™? (HAV™?) in Treatment of Patients with Vascular Trauma

Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic

Consensus revenue estimates fall by 33%

Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel (HAV) from Ukrainian Humanitarian Program

New major risk - Revenue size

First half 2023 earnings released: US$0.58 loss per share (vs US$0.17 profit in 1H 2022)

Humacyte, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel

Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair

Chief Operating Officer exercised options to buy US$240k worth of stock.

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.19 loss in 1Q 2022)

Humacyte, Inc. to Report Q1, 2023 Results on May 12, 2023

Price target decreased by 24% to US$7.35

Consensus revenue estimates decrease by 45%, EPS upgraded

Price target decreased by 15% to US$9.46

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Founder exercised options to buy US$321k worth of stock.

Investor sentiment improves as stock rises 15%

Humacyte, Inc. Announces Publication of 6-Year Outcomes of Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass, in Journal of Vascular Surgery – Vascular Science

Key Executive recently bought US$52k worth of stock

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 13%

High number of new directors

Price target decreased to US$10.13

Consensus EPS estimates fall by 12%

Humacyte, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Humacyte: Intriguing Potential

Humacyte, Inc. Announces New Board Appointments

Investor sentiment improved over the past week

Independent Director recently bought US$193k worth of stock

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 126%

Price target decreased to US$11.25

Second quarter 2022 earnings released: EPS: US$0.36 (vs US$0.76 loss in 2Q 2021)

Humacyte GAAP EPS of $0.35, revenue of $1.3M

Humacyte, Inc. to Report Q2, 2022 Results on Aug 12, 2022

High number of new directors

Humacyte, Inc. Announces Results Evaluating the Use of the Small-Diameter (3.5mm) Human Acellular Vessel for Coronary Artery Bypass Grafting in a Non-Human Primate Model

High number of new directors

Humacyte, Inc. Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel(TM) (HAV(TM)) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

Humacyte, Inc. Appoints Diane Seimetz to its Board of Directors

Humacyte, Inc. Presents New Immunogenicity Data on Human Acellular Vessels(Tm) (Havs(Tm))

First quarter 2022 earnings: EPS and revenues exceed analyst expectations